Multiple myeloma survivor and patient advocate Valarie Traynham returns for part 2 to share her insights on what action can be taken to create change in clinical research inequities. Valarie dives into the critical need to raise awareness about disparities in access and representation. She offers actionable ideas for improving healthcare support, building trust, and empowering historically marginalized communities through education and inclusion.

We’re joined by Valarie Traynham, a multiple myeloma survivor and passionate patient advocate, for the first of a two-part episode in a conversation on equity in healthcare and clinical research. Valarie explores the historical and systemic roots of medical mistrust and how they continue to impact clinical trial participation among racially diverse communities and people with disabilities. She sheds light on the misconceptions that discourage participation and offers thoughtful solutions for building trust and improving access to clinical trials.

In Part 2 of our conversation with Dr. Breelyn Wilky and Dr. Christopher Lieu from the University of Colorado Cancer Center, we dive deeper into the patient experience and the innovation behind clinical trials. They share guidance on when to consider a trial during your cancer journey, what a “day in the life” looks like for trial participants, and how trials differ from standard treatments like chemotherapy or radiation.

We also explore the unique role of investigator-initiated trials—what they are, how they differ from pharmaceutical-sponsored studies, and why they’re essential for advancing personalized cancer care.